Table 1.
Demographic features of SSc patients analyzed by SomaLogic, the initial and extended validation cohorts.
| Aptamer cohort (n = 6) |
First validation cohort (n = 30) |
Extended validation cohort (n = 89) | |
|---|---|---|---|
| Female, n (%) | 6 (100) | 26 (87) | 82 (92) |
| Age, median (IQR) | 64.5 (41-73) | 63.5 (48-75) | 64 (52-73.5) |
| dcSSc, n (%) | 1 (17) | 7 (23) | 17 (19) |
| Sine scleroderma, n (%) | 0 (0) | 4 (13) | 20 (22) |
| ACA, n (%) | 3 (50) | 14 (47) | 47 (53) |
| Anti-Scl-70, n (%) | 2 (33) | 13 (43) | 30 (34) |
| Anti-RNA polymerase III, n (%) | 0 (0) | 3 (10) | 6 (7) |
| Early SSc, n (%) | 3 (50) | 14 (47) | 38 (43) |
| ILD, n (%) dcSSc with ILD, n (%) |
3 (50) 1 (17) |
12 (40) 2 (7) |
30 (34) 10 (11) |
| Cardiomyopathy, n (%) | 1 (17) | 6 (20) | 17 (19) |
| PAH, n (%) | 0 (0) | 2 (7) | 14 (16) |
| Gastrointestinal involvement, n (%) | 5 (83) | 14 (47) | 43 (48) |
| Cancer, n (%) | 1 (17) | 5 (17) | 14 (16) |
ACA, anticentromere antibodies; dcSSc, diffuse cutaneous subset of SSc; ILD, interstitial lung disease; IQR, interquartile range; PAH, pulmonary arterial hypertension.